Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.5% in the afternoon session after several analysts raised their price targets on the stock, pointing to a more optimistic outlook for the ...

Fintel reports that on December 22, 2025, Canaccord Genuity maintained coverage of 10x Genomics (NasdaqGS:TXG) with a Buy recommendation. Analyst Price Forecast Suggests 3.60% Upside As of December 21 ...

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. 10x Genomics, Inc. is one of the seven stocks on our list of most promising stocks. On December 15, 2025, ...

Fintel reports that on December 11, 2025, Citigroup downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from Buy to Neutral. Analyst Price Forecast Suggests 1.96% Upside As of December 6, 2025, ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 6.3% in the morning session after Citigroup downgraded the stock to Neutral from Buy. The analyst firm adjusted its rating on the life science ...

We recently published 10 Stocks Beating the Market with Eye-Popping Gains. 10x Genomics Inc. (NASDAQ:TXG) is one of the best-performing stocks on Monday. Shares of 10x Genomics propelled to a new ...

10x Genomics is a life sciences technology company focused on the high-resolution analysis of biological systems. It leverages proprietary microfluidics and software to empower researchers with ...

Police are investigating the death of a man who reportedly fell down an elevator shaft at the shuttered Southwest Detroit Hospital on 20th Street in Corktown July 12. The hospital, closed since 2006, ...

On Friday, Cathie Wood-led Ark Invest made some significant trades. The most prominent among these were in Tesla Inc. (NASDAQ:TSLA), 10X Genomics Inc. (NASDAQ:TXG), Intellia Therapeutics Inc.

All 260 employees have been accounted for and have been provided with food. LONDON -- Hundreds of workers remain underground at the Kloof gold mine near Johannesburg after a "shaft incident" occurred ...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption, ...

Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...